Table 1 Patients and manufacturing process characteristics

Number of patients

20

Disease

B cell malignancies (B-ALL in 19 patients, DLBCL in 1 patient)

Age (mean, years)

13

Weight (mean, kg)

45.9

Sex

8F/12M

Race

White

13

Asian

2

AA

2

UNK

2

Multiple

1

Ethnicity

NH

14

H

6

Prior HSCT

10/20

Prior CAR T-cell therapy

15/20

Expansion method

Bag culture

Dose

0.3 × 10⁶/kg

Starting material

CliniMACS enriched CD4/CD8

Media and cytokines

AimV, IL2

Stimulation

CD3/CD28 Dynabeads

Length of the culture

9 days

Vector

Lentivirus